PYC Therapeutics Future Growth

Future criteria checks 2/6

PYC Therapeutics is forecast to grow earnings and revenue by 36.8% and 31% per annum respectively. EPS is expected to grow by 42.8% per annum. Return on equity is forecast to be -26.6% in 3 years.

Key information

36.8%

Earnings growth rate

42.8%

EPS growth rate

Biotechs earnings growth	15.7%
Revenue growth rate	31.0%
Future return on equity	-26.6%
Analyst coverage	Low
Last updated	14 Dec 2024

Recent future growth updates

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Earnings and Revenue Growth Forecasts

ASX:PYC - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	42	-11	-19	3	3
6/30/2026	35	-19	-37	-29	4
6/30/2025	9	-48	-39	-44	4
6/30/2024	22	-38	-39	-39	N/A
3/31/2024	22	-30	-29	-29	N/A
12/31/2023	21	-22	-20	-19	N/A
9/30/2023	19	-22	-22	-22	N/A
6/30/2023	16	-23	-25	-24	N/A
3/31/2023	15	-23	-26	-25	N/A
12/31/2022	14	-24	-26	-26	N/A
9/30/2022	15	-19	-24	-24	N/A
6/30/2022	16	-14	-22	-22	N/A
3/31/2022	13	-15	-18	-17	N/A
12/31/2021	9	-17	-14	-13	N/A
9/30/2021	6	-17	-13	-12	N/A
6/30/2021	3	-18	-12	-12	N/A
3/31/2021	3	-15	-11	-11	N/A
12/31/2020	2	-12	-10	-10	N/A
9/30/2020	2	-9	-8	-8	N/A
6/30/2020	2	-7	-6	-6	N/A
3/31/2020	1	-6	-6	-6	N/A
12/31/2019	0	-5	-6	-6	N/A
9/30/2019	0	-5	-6	-6	N/A
6/30/2019	N/A	-4	-6	-5	N/A
3/31/2019	0	-4	-4	-4	N/A
12/31/2018	0	-5	-3	-3	N/A
9/30/2018	0	-6	-5	-5	N/A
6/30/2018	0	-7	-7	-7	N/A
3/31/2018	0	-6	N/A	-5	N/A
12/31/2017	0	-5	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	3	-2	N/A	-2	N/A
3/31/2017	3	-3	N/A	-4	N/A
12/31/2016	3	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	0	-4	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-4	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	1	-3	N/A	-2	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-3	N/A	-4	N/A
9/30/2014	1	-3	N/A	-4	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-3	N/A
12/31/2013	1	-3	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PYC's revenue (31% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: PYC's revenue (31% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PYC is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/29 04:38
End of Day Share Price	2024/12/27 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PYC Therapeutics Limited is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Wakim	Bell Potter
Elyse Shapiro	Canaccord Genuity
Michael Thomas Cooper	Edison Investment Research

PYC Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 165% to AU$8.75

Price target increased by 8.2% to AU$0.33

Price target increased by 9.1% to AU$0.30

Price target decreased by 15% to AU$0.29

Forecast to breakeven in 2026

Recent updates

Price target increased by 165% to AU$8.75

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes